Cesca Therapeutics Announces Exhibition at The Orthobiologic Institute’s 9th Annual PRP & Regenerative Medicine Symposium
June 06 2018 - 8:30AM
Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a
market leader in automated cell processing and point-of-care,
autologous cell-based therapies, today announced that the Company
will be exhibiting its development-stage PXP™ System at The
Orthobiologic Institute’s (TOBI) 9th Annual PRP & Regenerative
Medicine Symposium with Workshops & Cadaver Labs, which is
being held June 7-9 in Las Vegas.
“In a mini review recently published in the
peer-reviewed Journal of Orthopedic Research and Therapy, we report
on the role of various bone marrow derived cells and cytokines used
in the treatment of different orthopedic indications, such as knee
osteoarthritis,” said Dalip Sethi, Ph.D., Senior Director of
Research and Development at Cesca. “Previous studies have
identified a relationship between the presence of contaminating red
blood cells (RBCs) and the decreased functionality of the stem and
progenitor cells. The negative effect of contaminating RBCs is
being discussed and debated in the field. To better understand the
future potential of autologous stem cell-derived therapies, there
is an urgent need for cell processing systems capable of extracting
target cells with a higher degree of viability and purity. Cesca is
pioneering this effort with its PXP System, for the processing of
autologous bone marrow aspirates. As such, we are pleased to be
able to exhibit this novel technology at this year’s TOBI
symposium.”
Cesca’s PXP System, once development is
completed, will allow for the rapid processing of autologous bone
marrow cells at the point-of-care. The System, which automates the
volume reduction process, ensures consistently high recoveries of
mononuclear cells (MNC), enriched in stem and progenitor cells. The
System delivers a targeted volume and is capable of simultaneously
processing multiple bone marrow units. The System does not require
cell separation media or sedimentation agents.
The full text of the publication can be found at
this link: Bone Marrow Concentrate for Treatment of Knee
Osteoarthritis: A Mini Review
More information about the 2018 TOBI Symposium
can be found here.
About TOBI 2018The
Orthobiologic Institute’s PRP & Regenerative Medicine Symposium
is an annual gathering of approximately 500 clinicians,
researchers, and industry professionals seeking to learn
cutting-edge research and best practices in orthobiologic
regenerative medicine.
About Cesca Therapeutics
Inc. Cesca
Therapeutics Inc. (the “Company”) develops, commercializes and
markets a range of automated technologies for CAR-T and other
cell-based therapies. Its device division, ThermoGenesis Corp.,
provides a full suite of solutions for automated clinical
biobanking, point-of-care applications, and automation for
immuno-oncology. The Company is developing an automated,
functionally-closed CAR-TXpress™ platform to streamline the
manufacturing process for the emerging CAR-T immunotherapy
market.
Company Contact: Cesca Therapeutics Inc. Wendy
Samford916-858-5191ir@cescatherapeutics.com
Investor Contact: Rx CommunicationsPaula
Schwartz917-322-2216pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Sep 2023 to Sep 2024